tbuckley/cabot-search huggingface dataset:
Investigation of a possible link between epithelial four-and-a-half LIM domains protein 2 expression and prognosis in colorectal cancer.
Authors: Laurine Verset, Joke Tommelein, Xavier Moles Lopez, Christine Decaestecker, Marc Mareel, Marc Bracke, Isabelle Salmon, Olivier De Wever, Pieter Demetter
Journal: Journal of Clinical Oncology (2013)

401 Background: Four-and-a-half LIM domains protein 2 (FHL2) is a component of the focal adhesion structures and has been suggested to play a role in cancer progression. It has been shown to be overexpressed in colorectal cancer (CRC). Here we examined a possible prognostic value of FHL2 in CRC. Methods: Immunohistochemistry for FHL2 was performed on 296 CRCs without distant metastases at time of surgery. Staining in the epithelial compartment was quantitatively evaluated using image analysis, and results were related to clinical variables. Antibody specificity was tested using siRNA transfection in hTERT-immortalised myofibroblasts. FHL2 expression was investigated also by Western blotting in sporadic (HT29) and HNPCC-derived (HCT116 and HCT8/E11) colon cancer cell lines. Results: Varying degrees of cytoplasmic FHL2 expression by neoplastic epithelial cells were detectable in all cases. Higher FHL2 expression in the epithelial compartment was an independent adverse prognostic factor. Expression in the tumour invasion front (p &lt; 0.001) as well as in the centre of the tumour (p &lt; 0.001) was associated with metachronous metastases. No relation between FHL2 expression and microsatellite instability could be demonstrated. Conclusions: Higher FHL2 expression is involved in CRC progression and correlates with the development of metachronous metastases, suggesting that FHL2 is an independent adverse prognostic indicator for CRC.
Less invasive investigation of perinatal death
Authors: Owen J Arthurs, Charlotte Bevan, Neil J Sebire
Journal: BMJ (2015)

Emphasis is shifting to a service driven by parental acceptability and involvement

Whether a baby is stillborn (dies before or during labour after 24 weeks of pregnancy) or dies in early life (a neonatal death) bereaved parents may not be best served by current approaches to investigating their baby’s death. The NHS routinely offers standard autopsy, with incisions to the body to examine internal organs. Although this type of perinatal autopsy provides useful additional information in 30-40% of cases, a falling minority of parents agree to it.1 Some do agree, for altruistic as well as personal reasons—they hope that their child’s postmortem examination may contribute to the body of research that will shape future prevention.

Preliminary results from Europe indicate that almost all parents who decline standard autopsy, and are currently not offered an alternative, would agree to a less invasive autopsy.2 3 This comprises postmortem imaging and ancillary tests, with or without tissue biopsy. Less invasive autopsy has considerable implications for future clinical practice, because it could provide additional diagnostic information for more families as well as for public health and for evaluating the quality of obstetric and neonatal care, where data are …
Clinical Study Of Dose-Adjusted EPOCH Regimen For Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis: Preliminary Results Of An Ongoing Phase II Study
Authors: Wei Xu, Lei Fan, Li Wang, Ji Xu, Run Zhang, Yuqiong Yang, Dongping Huang, Yunfeng Shen, Min Zhou, Liang Yu, Zhihong Zhang, Jianyong Li
Journal: Blood (2013)
Role of inflammatory infiltrating cells in toxic experimental interstitial fibrosis (aristolochic acids)
Authors: Joëlle Nortier, Agnieszka Pozdzik, Frédéric Debelle, Marie-Françoise Bourgeade, Isabelle Salmon, Monique Deschodt Lanckman, Jean-Louis Vanherweghem
Journal: Journal of the American Society of Nephrology (2005)
FACTORS INFLUENCING THE FATALITY RATE OF PNEUMOCOCCIC PNEUMONIA TREATED WITH SULFONAMIDE COMPOUNDS
Authors: Harrison F. Flippin, Leon Schwartz, Jefferson H. Clark
Journal: Annals of Internal Medicine (1941)

Article1 May 1941FACTORS INFLUENCING THE FATALITY RATE OF PNEUMOCOCCIC PNEUMONIA TREATED WITH SULFONAMIDE COMPOUNDSHARRISON F. FLIPPIN, M.D., F.A.C.P., LEON SCHWARTZ, M.D., JEFFERSON H. CLARK, M.D., F.A.C.P.HARRISON F. FLIPPIN, M.D., F.A.C.P.Search for more papers by this author, LEON SCHWARTZ, M.D.Search for more papers by this author, JEFFERSON H. CLARK, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-11-1969 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe introduction of sulfapyridine and sulfathiazole in the treatment of pneumococcic pneumonia constitutes the greatest advance in the control of this disease. Within the past three years numerous clinical reports have unquestionably established their therapeutic effectiveness, and the fatality rate of pneumococcic pneumonia has been markedly reduced with their use. Despite the proved value of this form of therapy, a certain percentage of pneumonia patients in whom these drugs are employed fail to recover. The purpose of this paper is to discuss the influence of several factors on the prognosis of this disease. This report is based on our experience...References1. EVANSGAISFORD GMWF: Treatment of pneumonia with 2-p (aminobenzenesulfonamido) pyridine, Lancet, 1938, ii, 14. CrossrefGoogle Scholar2. FLIPPINLOCKWOODPEPPERSCHWARTZ HFJSDSL: Treatment of pneumococcic pneumonia with sulfapyridine, Jr. Am. Med. Assoc., 1939, cxii, 529. CrossrefGoogle Scholar3. PLUMMERENSWORTH NHK: Sulfapyridine in the treatment of pneumonia, Jr. Am. Med. Assoc., 1939, cxiii, 1854. Google Scholar4. SCHWARTZFLIPPINTURNBULL LHFWG: The treatment of pneumococcic pneumonia: a comparative study of 351 patients treated at the Philadelphia General Hospital, ANN. INT. MED., 1939, xiii, 1005. Google Scholar5. FLIPPINSCHWARTZROSE HFLSB: The comparative effectiveness and toxicity of sulfathiazole and sulfapyridine in pneumococcic pneumonia, ANN. INT. MED., 1940, xiii, 2038. Google Scholar6. FLIPPINREINHOLDSCHWARTZ HFJGL: Sulfapyridine and sulfathiazole therapy in pneumococcic pneumonia, Jr. Am. Med. Assoc., 1941, cxvi, 683. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, Pennsylvania*Received for publication December 20, 1940.From the Committee for the Study of Pneumonia, Philadelphia General Hospital.Aided by a grant from the American Philosophical Society. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPneumonia at the Philadelphia General Hospital, 1936–1946 1 May 1941Volume 14, Issue 11Page: 1969-1974KeywordsDrug therapyPneumoniaSulfonamide ePublished: 1 December 2008 Issue Published: 1 May 1941 Copyright & PermissionsCopyright, 1941, by The American College of PhysiciansPDF downloadLoading ...
THE IMPORTANCE OF ACTUALLY MEASURING THE TOTAL HEAT PRODUCTION
Authors: L. H. Newburgh
Journal: Annals of Internal Medicine (1934)

Article1 October 1934THE IMPORTANCE OF ACTUALLY MEASURING THE TOTAL HEAT PRODUCTIONL. H. NEWBURGHL. H. NEWBURGHSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-8-4-459 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA knowledge of the basal metabolism is informative in many different problems. Its diagnostic value is quite familiar; but its use as a basis for estimating the total production of heat is open to errors which are sometimes so large that the observer is seriously misled.In the pursuit of our own studies, it became of paramount importance to be possessed of a means of knowing accurately how much energy was dissipated day after day so that we could compare the inflow of calories with their expenditure. This we were able to do by the development of Benedict's1study of...References1. BENEDICTROOT FGHF: Insensible perspiration; its relation to human physiology and pathology, Arch. Int. Med., 1926, xxxviii, 1-35. CrossrefGoogle Scholar2. NEWBURGHWILEYLASHMET LHFHFH: Method for determination of heat production over long periods of time, Jr. Clin. Invest., 1931, x, 703-721. CrossrefGoogle Scholar3. LUSK G: The elements of the science of nutrition, 4 Ed., 1928, W. B. Saunders, Philadelphia, page 465. Google Scholar4. GRAFE E: Metabolic diseases and their treatment, 1933, Lea and Febiger, Philadelphia. Google Scholar5. NEWBURGHJOHNSTON LHMW: Nature of obesity, Jr. Clin. Invest., 1930, viii, 197-213. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Ann Arbor, Michigan*Read at the Chicago meeting of the American College of Physicians, April 17, 1934. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe treatment of obesity: An analysis of methods, results, and factors which influence success 1 October 1934Volume 8, Issue 4Page: 459-467 Issue Published: 1 October 1934 PDF downloadLoading ...
Abstract 12638: Serum Low-density Lipoprotein to High-density Lipoprotein Ratio is a Potential Indicator For Reduction of Renal Damage Progression in Patients With Acute Myocardial Infarction
Authors: Satoshi Okumura, Ryo Hayashida, Yasushi Jinno, Akihito Tanaka, Koji Okada, Masaki Sakakibara
Journal: Circulation (2011)

Introduction: Statin therapy improves serum cholesterol levels and reduces the progression of renal damage. Serum low-density lipoprotein to high-density lipoprotein ratio (L/H) is a useful indicat...
ATOPIC ANNOYANCES IN THE COURSE OF PULMONARY TUBERCULOSIS
Authors: E. W. Phillips
Journal: Annals of Internal Medicine (1935)

Article1 June 1935ATOPIC ANNOYANCES IN THE COURSE OF PULMONARY TUBERCULOSISE. W. PHILLIPS, M.D., F.A.C.P.E. W. PHILLIPS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-8-12-1649 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe word "atopic" is used in this paper to characterize spontaneous acquired sensitization to a foreign protein. This is an extension of Coca's1 definition; but "allergy" means one thing to the allergist, another to the immunologist. For the purpose of the present discussion it is desirable to employ a term that excludes the delayed inflammatory reaction of the infected individual to tuberculoprotein, a reaction which students of tuberculosis generally describe as "allergic."Atopic manifestations, especially hay fever, are often seen in cases of pulmonary tuberculosis. In 1925 I recorded the study,2from the viewpoint of the allergist, of a series...Bibliography1. COCA AF: Asthma and hay fever in theory and practice, Part 1, 1931, Charles C. Thomas, Baltimore. Google Scholar2. PHILLIPS EW: Pulmonary tuberculosis complicated by asthma, Southwest. Med., 1925, ix, 215-218. PHILLIPS, E. W.: Relief of hay fever by intradermal injections of pollen extract, Jr. Am. Med. Assoc., 1926, lxxxvi, 182-184. Google Scholar3. ROWE AH: Food allergy, 1933, Lea and Febiger, Philadelphia. Google Scholar4. VAUGHAN WT: Minor allergy: its distribution, clinical aspects and significance, Jr. Allergy, 1934, v, 184-196. CrossrefGoogle Scholar5. SHERMANEGBERT JEOE: Some clinical aspects of nontuberculous allergy in tuberculosis, Am. Rev. Tuberc., 1934, xxx, 561-565. Google Scholar6. PHILLIPS EW: Hay fever in central Arizona, Southwest. Med., 1923, vii, 273-281. PHILLIPS, E. W.: Pollen incidence in central Arizona, Jr. Allergy, 1932, iii, 489-494. Google Scholar7. DURHAM OC: Ragweed season of 1932 in United States, Canada, and Mexico, Jr. Allergy, 1932, iv, 105-113. Google Scholar8. LICHTENSTEIN MR: Intravenous pollen therapy, Jr. Allergy, 1934, v, 230-239. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Phoenix, Arizona*Received for publication January 7, 1935.From St. Luke's Home, Phoenix, Arizona. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1935Volume 8, Issue 12Page: 1649-1658KeywordsAllergy and immunologyFeversProteinsTuberculosis ePublished: 1 December 2008 Issue Published: 1 June 1935 PDF downloadLoading ...
Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors
Authors: R. B. Hegeman, D. Mulkerin, J. Thomas, D. Alberti, K. Binger, R. Marnocha, J. Kolesar, G. Wilding
Journal: Journal of Clinical Oncology (2005)

2058 Background: The combination of oxaliplatin with bolus and infusional 5-FU has shown high activity in 1st and 2nd line therapy of advanced colon cancer. A phase I study has been completed evaluating the combination of oxaliplatin, bolus 5-FU, LV, and capecitabine administered on a novel high dose intensity schedule designed to mimic FOLFOX-6. Methods: 36 patients with advanced or metastatic solid tumors received 1 of 2 regimens: A) oxaliplatin 100 mg/m2, 5-FU bolus 400 mg/m2, and LV 200 mg/m2 all given IV on days 1 and 15 of a 28 day schedule, and capecitabine in escalating doses given orally three times daily for 6 doses on days 1–2 and 15–16 of same cycle; or B) oxaliplatin at same dose and schedule as above with escalating doses of capecitabine only. Schedule B was adopted to determine whether greater dose intensity of capecitabine could be achieved in the absence of bolus 5-FU and LV. Pharmacokinetic parameters for capecitabine and its metabolites have been collected. Full pharmacokinetic analysis will be presented. Results: Dose-limiting toxicities in group A were nausea, dehydration, fatigue, and hypertension, occurring at capecitabine dose of 2250 mg/m2. Dose-limiting toxicities in group B were neutropenia and fatigue occurring at capecitabine dose of 3375 mg/m2, and 1 of 10 patients at capecitabine dose of 2250 mg/m2 experienced a dose-limiting toxicity of grade 4 neutropenia. Overall, the most common grade 3 or 4 toxicities at least possibly related to treatment were neutropenia, nausea, vomiting, diarrhea, dehydration, fatigue, and thrombocytopenia. There was 1 complete response (gastric cancer) and 3 partial responses noted. Conclusions: Substituting capecitabine for infusional 5-FU in a novel high dose schedule designed to mimic FOLFOX-6 is a feasible and well tolerated treatment. Dose escalation of capecitabine was possible with the deletion of bolus 5-FU and LV. The proposed phase II dose for capecitabine in combination with oxaliplatin, 5-FU, and LV is 1500 mg/m2, or 2250 mg/m2 in the absence of 5-FU/LV. Study supported by NCI-UO1-CA062491 and NIH-M01-RR03186. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sanofi-Synthelabo
Abstract 8413: Differences in Myocyte Enhancer Factor-2 and Nuclear Factor of Activated T Cells Pathways According to Human Heart Failure Aetiology
Authors: Miguel Rivera, Raquel Cortes, Esther Rosello, Inmaculada Azorin, Antonio Salvador, Luis Almenar, Luis Martinez-Dolz, Jose Gonzalez-Juanatey, Francisca Lago, Ignacio Sanchez-Lazaro, Leif Hove, Vicente Bertomeu, Anastasio Montero, Juan Cinca, Manuel Portoles
Journal: Circulation (2011)

Introduction: Ca 2+ handling machinery modulates the activation of cardiac transcription pathways involved in heart failure (HF). The present study investigated the effect of HF aetiology on Ca +2 handling proteins and nuclear factor of activated T cells-1 (NFAT1), myocyte enhancer factor-2 (MEF2C) and transcription factor GATA-4 (GATA4); all transcription factors in the same cardiac tissue. Methods: A total of 80 hearts from ischaemic (ICM, n = 43) and dilated (DCM, n = 31) patients undergoing heart transplantation and controls (n = 6) were analysed by western blotting. Subcellular distribution was analysed by fluorescence and electron microscopy. Results: We compared Ca +2 handling proteins according to HF aetiology, ICM showed higher levels of calmodulin (27%, p&lt;0.05), calcineurin (22%, p&lt;0.05) and Ca 2+ /Calmodulin-dependent kinase II (CaMKIIδ b nuclear isoform 96%, p&lt;0.01) than control group. However, these proteins in DCM did not significantly increase. Furthermore, ICM showed a significant elevation in MEF2C (23%, p&lt;0.05), and GATA4 (51%, p&lt;0.05); also NFAT1 (53%, p&lt;0.01) was increased, producing the resultant translocation of this transcriptional factor into the nuclei. These results were supported by fluorescence and electron microscopy analysis. In addition, DCM only had a significant increase in GATA4 (52%, p&lt;0.05). Correlations between NFAT1 and MEF2C in both groups (ICM r=0.36 and DCM r=0.51, p&lt;0.05) were found; only ICM showed a correlation between GATA4 and NFAT1 (r=0.42, p&lt;0.05). Conclusions: This study shows an activation of Ca 2+ handling machinery synthesis and their cardiac transcription pathways in HF, being more markedly increased in ICM. Furthermore, there is a significant association between MEF2, NFAT1 and GATA4. These proteins could be therapeutic targets to improve myocardial function.
Familial Myeloma
Authors: Henry T. Lynch, Kelly Ferrara, Bart Barlogie, Elizabeth A. Coleman, Jane F. Lynch, Dennis Weisenburger, Warren Sanger, Patrice Watson, Henry Nipper, Vinetta Witt, Stephan Thomé
Journal: New England Journal of Medicine (2008)

We describe a family with five cases of multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS), and five cases of prostate cancer in two generations. The putative progenitor had progeny with two female partners. The progeny had prostate cancer, multiple myeloma, and MGUS.
Factor XIII gene variation and the risk of venous thrombosis.
Authors: Maria Carolina T. Pintão, Ricardo V. Reges, Marli Haydee Tavella, Amélia Goes Araújo, Vânia M. Morelli, Dayse Maria Lourenço, Francisco Humberto de Abreu Maffei, Marco Antônio Zago, Rendrik França Franco
Journal: Blood (2003)
Advanced CML: therapeutic options for patients in accelerated and blast phases.
Authors: Neil P Shah
Journal: Journal of the National Comprehensive Cancer Network (2008)

Tyrosine kinase inhibitor (TKI) therapy has impacted the natural course of chronic myelogenous leukemia (CML), because patients diagnosed as having chronic-phase disease can experience long-lasting responses. However, for patients with advanced CML (accelerated and blast phases), the efficacy of all current therapies is reduced. For these patients, allogeneic stem cell transplantation remains the preferred treatment if a donor is available, although TKIs play a valuable role as a bridging therapy. For patients with accelerated-phase CML, imatinib, dasatinib, and nilotinib have been shown to produce meaningful rates of hematologic and cytogenetic response. Imatinib and dasatinib are also approved for blast-phase CML. Studies with the newer agents have involved heavily pretreated patients; however, response rates have been at least comparable to those achieved with imatinib in previous studies. Therefore, these newer, more potent TKIs will probably be more likely to induce a deep response in previously untreated patients. Moreover, because fewer mechanisms appear to exist for secondary resistance to dasatinib and nilotinib, reducing the potential for disease to escape TKI therapy, these agents may result in improved longer-term outcomes. However, BCR-ABL-independent pathways may also become more important, indicating that other therapeutic targets may also have a future role in managing patients with advanced CML.
Abstract 5952: Fibrotic Atherosclerotic Lesion Exacerbates Large Arterial Stiffening Following Aortic Constriction In Apolipoprotein E Deficient Mice
Authors: Qi Xu, Xiaoming Gao, Ziqiu Ming, Helen Kiriazis, Xiao-Jun Du, Anthony M Dart
Journal: Circulation (2008)

Hypertension, particularly systolic hypertension, is known to be a major risk factor for the development of atheroma. The effects of aortic atheroma on large arterial stiffness remain unclear. We introduced pressure overload in apoE −/− mice by transverse (TAC) or abdominal aorta constriction (AAC) for a period of 12-weeks. TAC led to 107% and 119% increase of pulse pressure, and AAC led to 55% and 51% increase of pulse pressure in wild-type and apoE −/− mice, respectively (all P &lt;0.01), accompanied by a 3–4 fold increase of lesion area in apoE −/− mice (19.2±3.9% in TAC and 15.9±4.0% in AAC vs. 5.2±0.9% in sham-operation, all P &lt;0.05). The lesion area correlated significantly with pulse pressure, but not with mean blood pressure (Fig ). Interestingly, plaque in TAC mice was fibrotic, while plaque in mice subjected to AAC was lipid-rich with a histology associated with plaque instability (Fig ). Furthermore, Apoe −/− mice post-TAC showed a more stiffened aorta than wild-type counterparts, evidenced by a greater degree of reduction in augmentation time (6.5±0.2 ms vs. 7.7±0.5 ms, P &lt;0.05) and a greater degree of increment in augmentation index (77±2% vs. 71±2%, P &lt;0.05). However, no such differences were observed between large artery stiffness in wild-type and Apoe −/− mice post-AAC. Our results show that different features of plaques developed in TAC and AAC models differing in PP only, and fibrotic plaques in Apoe −/− mice with TAC were associated with more pronounced large arterial stiffening. Plaque with thick layer of smooth muscle cells (SMC) in TAC vs lipid-rich plaque in AAC. Arrows indicate the organized blood clot in the expanded adventitial tissue due to plaque rupture.
Abstract 1976: Characteristics and Distribution of the Scar Tissue Detected by Magnetic Resonance Imaging may Predict Ventricular Tachycardia in Patients with Advanced Heart Failure
Authors: Miki Yokokawa, Hiroshi Tada, Keiko Koyama, Shigeto Naito, Shigeki Hiramatsu, Koji Goto, Shigeru Oshima, Koichi Taniguchi
Journal: Circulation (2007)

Introduction: Contrast-enhanced magnetic resonance imaging (CMR) reveals scar tissue as an enhanced area. Non-transmural scar regions may link to a scar-related reentrant ventricular tachycardia (VT). Methods: CMR was performed in 46 patients with advanced heart failure (dilated cardiomyopathy [DCM]-30, ischemic cardiomyopathy [ICM]-16; 36 males, 65±12 yrs; EF 28±12 %). Twenty-one patients (46 %) had documented sustained VTs. The scar volume (%; the percentage of the total scar volume) was obtained using MRI software. CMR images were also scored visually according to a 17-segment model (transmural score: 0= no damage, 4= transmural scar). The total number (No.) of segments with a transmural score of 4 (transmural scar) and transmural score of 1–3 (non-transmural scar), and the percentage of segments with non-transmural scar were obtained. The CMR parameters and clinical arrhythmic events were compared between the patients with DCM (DCM-Gr) and ICM (ICM-Gr). Results ( Table ): In the DCM-Gr, the scar was usually non-transmural, which presented mainly in the mid-wall layer and was characterized by a patchy distribution. The scar volume and total No. of segments with non-transmural scar were greater in DCM patients with VT than in those without. In contrast, patients in the ICM-Gr had transmural or subendocardial enhancement in the territory of coronary arteries, and the scar volume was smaller in ICM patients with VT than in those without. However, the total No. of segments with non-transmural scar and percentage of segments with non-transmural scar were greater in ICM patients with VT than in those without. In the VT patients in both Grs, non-transmural scar was always found at the VT exit site. Conclusions: CMR is useful for assessing the characteristics and distribution of myocardial scar. A wider and greater distribution of the non-transmural scar may provide the potential substrate for reentrant VTs in patients with advanced heart failure. Table: CMR-parameters in Patients with DCM and ICM